Prevention of Future Deaths reports · 2025
Regulation 28 report to prevent future deaths, reference 2025-0121, written 4 Mar 2025. A coroner writes one of these when an inquest reveals a risk that could cause further deaths unless something changes.
| Date of report | 4 Mar 2025 |
|---|---|
| Reference | 2025-0121 |
| Deceased | Chloe Burgess |
| Coroner | Nicholas Walker |
| Coroner area | Hampshire, Portsmouth and Southampton |
| Category | Alcohol, drug and medication related deaths |
| Source | judiciary.uk record · original PDF |
| Responses published | 2 |
Text extracted from the PDF text layer. Reproduced verbatim, including the scan's own layout.
REGULATION 28: REPORT TO PREVENT FUTURE DEATHS (1) REGULATION 28 REPORT TO PREVENT FUTURE DEATHS THIS REPORT IS BEING SENT TO: 1. National Institute for Health and Care Excellence and the British National Formulary, 3rd floor,3 Piccadilly Place, Manchester, M1 3BN 2. London office Royal College of Physicians 11 St Andrews Place Regent's Park London NW1 4LE 1 CORONER I am Nicholas Walker, Area Coroner, for the coroner area of Hampshire, Portsmouth and Southampton. 2 CORONER’S LEGAL POWERS I make this report under paragraph 7, Schedule 5, of the Coroners and Justice Act 2009 and Regulations 28 and 29 of the Coroners (Investigations) Regulations 2013. 3 INVESTIGATION and INQUEST On 19th September 2023 an investigation was commenced into the death of Chloe Elizabeth Burgess. The investigation concluded at the end of the inquest on 12th February 2025. The conclusion of the inquest was that the effect of medication in combination contributed to Chloe’s death. 4 CIRCUMSTANCES OF THE DEATH Chloe Elizabeth Burgess was found deceased at home at Southampton, Hampshire on 8th September 2023. Chloe was prescribed heart medication after a diagnosis of sinus tachycardia and left bundle branch block as well as antidepressant medication. It is likely that the medication interacted with each other to raise the levels of amitriptyline in Chloe’s blood which, combined with her heart medication and an episode of sleep apnoea, induced severe cardiac arrhythmia and sudden cardiac death. She had been using the combination of drugs for four years before she died without concern. The potential dangers of the combination of drugs in Chloe’s case was not well- known or appreciated by those treating her. . 5 CORONER’S CONCERNS During the inquest the evidence revealed matters giving rise to concern. In my opinion there is a risk that future deaths could occur unless action is taken. In the circumstances it is my statutory duty to report to you. The MATTERS OF CONCERN are as follows. – The inquest heard evidence that the potential dangers of the combination of amitriptyline, paroxetine and ivabradine is not widely appreciated and does not trigger an alert on the prescribing software used in primary care or by pharmacists. The potential dangers related to a failure to metabolise amitriptyline which can, incrementally, lead to toxicity. I am also concerned that those prescribing ivabradine should have a full understanding of the potential interaction with amitriptyline and paroxetine. 6 ACTION SHOULD BE TAKEN In my opinion action should be taken to prevent future deaths and I believe your organisation have the power to take such action. 7 YOUR RESPONSE You are under a duty to respond to this report within 56 days of the date of this report, namely by 28th April 2025 I, the coroner, may extend the period. Your response must contain details of action taken or proposed to be taken, setting out the timetable for action. Otherwise you must explain why no action is proposed. 8 COPIES and PUBLICATION I have sent a copy of my report to the Chief Coroner and to the following Interested Persons: The family of Chloe Burgess I am also under a duty to send the Chief Coroner a copy of your response. The Chief Coroner may publish either or both in a complete or redacted or summary form. He may send a copy of this report to any person who he believes may find it useful or of interest. You may make representations to me, the coroner, at the time of your response, about the release or the publication of your response by the Chief Coroner. 9 Signed by the Coroner 4th March 2025
2 responses published against this report on judiciary.uk. A response is a body's written reply to the coroner's concerns; publication is at the discretion of the Chief Coroner's office, so an absent response does not mean nobody replied.
2nd Floor 2 Redman Place London E20 1JQ United Kingdom 28 April 2025 Nicholas Walker Coroner’s Office The Castle Castle Hill Winchester SO23 8UL Dear Mr Walker, I write in response to your regulation 28 report, sent to NICE on 4 March 2025, regarding the very sad death of Chloe Elizabeth Burgess. I would like to offer my sincere condolences to Chloe’s family. We have reflected on the circumstances surrounding Chloe’s death, and the concerns raised in your report regarding drug interactions. The British National Formulary (BNF) provides key information on the selection, prescribing, dispensing and administration of medicines and we believe that they would be best placed to address your concerns. The BNF is a joint publication of the BMJ Group and Pharmaceutical Press, the publishing division of the Royal Pharmaceutical Society. While we make the BNF available on the NICE website, responsibility for the content remains with the publishers and therefore NICE cannot comment on the concerns you have raised. Your sincerely, Chief Executive
Care Quality Improvement Directorate Royal College of Physicians The Spine 2 Paddington Village Liverpool L7 3FA Tel: +44 (0)151 318 0000 Email: cqid@rcp.ac.uk www.rcp.ac.uk T: Nicholas Walker HM Area Coroner for Hampshire, Portsmouth and Southampton High Street The Castle Winchester SO23 8UJ Ref: 2025-0121 2nd May 2025 Royal College of Physicians response to Regulation 28 report to prevent future deaths Dear Mr Walker, The Royal College of Physicians (RCP) notes with concern the content of the Regulation 28 report for the prevention of future deaths related to the death of Chloe Elizabeth Burgess. We send our sincere condolences to the family of Ms Burgess. This regulation 28 report is addressed to the RCP, and we have consulted cardiovascular and pharmacology experts, as well as liaising with the Royal Pharmaceutical Society to appropriately respond. We note the matters of concern raised in this report, particularly that the potential dangers of the combination of amitriptyline, paroxetine and ivabradine are not widely appreciated and do not trigger an alert on the prescribing software used in primary care and/or by pharmacists. We also note that Chloe was known to have an electrical conducting abnormality of the heart, left bundle branch block an intraventricular conduction defect, which is in the BNF, lists as a ‘caution’ with the use of Ivabradine. Ivabradine | Drugs | BNF | NICE. Our experts noted that whist ivabradine is a pacemaker current (If) inhibitor, used for the symptomatic management of heart-related chest pain and heart failure, it is also used for inappropriate sinus tachycardia. We note that neither paroxetine or amitriptyline are listed as drugs interacting with ivabradine in the BNF Ivabradine | Interactions | BNF | NICE. The BNF is the recommended nationally used prescribing aid. This is often used as a reference source for prescribing software and is overseen by the joint formulary committee. Interactions between drugs which increase the concentration of ivabradine are well recognised and do appear in the BNF. Pharmaceutical colleagues also note that Stockley’s Drug Interactions table, accessed via the Medicines Complete website does not show a “life- threatening or contraindicated combination” between amitriptyline and ivabradine. It does suggest, on a theoretical basis, that “dosage adjustment or close monitoring is needed” as “the risk of QT-interval prolongation with amitriptyline might be exacerbated by bradycardia caused by ivabradine. If concurrent use is unavoidable, monitor cardiac effects (e.g. heart rate) closely.” We note your concerns regarding the potential dangers related to failure to metabolise amitriptyline which can, incrementally, lead to toxicity, and the need for those prescribing to have full understanding of the potential interactions. The interaction by which paroxetine is predicted to increase the concentration of amitriptyline is also well recognised and included in the BNF Amitriptyline | Interactions | BNF | NICE / Paroxetine | Interactions | BNF | NICE. Pharmacology colleagues consulted noted that ivabradine is metabolised by a different enzyme from amitriptyline and are not aware of it increasing the concentration of amitriptyline. As ivabradine slows the heart, they note that there is a theoretical risk of QT- interval prolongation (changes in the electrical coordination within the heart) with amitriptyline which might be exacerbated by bradycardia caused by ivabradine and may increase the likelihood of arrhythmias in drugs which increase the QT interval on the ECG. This is supported by ongoing research, referenced below1. The Royal Pharmaceutical Society, as joint publishers of the BNF have advised that pharmacokinetic (drug metabolism) interactions are included within the BNF, but that all theoretical compound effects of combinations of medications through their mode of action cannot be included. Furthermore, prescribing software for primary care and pharmacies is provided by independent commercial organisations, who will choose which reference materials they use to inform alerts. This software and its application is currently not regulated. It is the role of all prescribers to understand the overarching mechanisms of action of medicines they may prescribe, and where similar actions occur by more than one medicine, or might exacerbate pathology in individual patients, particular caution or monitoring should be instituted. It is important that they do not rely on prescribing software, but use recognised reference materials. The Royal College of Physicians works closely with the Royal Pharmaceutical Society, the British Pharmacological Society and NHS England Chief Pharmacists. We will discuss this case at our next Patient Safety Committee and Joint Medicines Safety Working Group, to explore whether further action should be taken informed by this case. 1 hERG potassium channel blockade by the HCN channel inhibitor bradycardic agent ivabradine - PubMed hERG potassium channel inhibition by ivabradine requires channel gating - PubMed hERG potassium channel inhibition by ivabradine may contribute to QT prolongation and risk of torsades de pointes - PubMed Yours sincerely, Clinical Vice President, Royal College of Physicians
See every Prevention of Future Deaths report matching Alcohol, drug and medication related deaths, and how often a new one appears.
What would an alert for this have sent me? Search the full text
Free to try — the preview shows the real matches and how many arrived in the last 12 months. Your first email alert is free.
These reports are published by the Chief Coroner's office at judiciary.uk and are © Crown copyright. The text here is reproduced from the published PDF so it can be searched. If something on this page is wrong, or you are a person named in it and want it reviewed, email drcjar@gmail.com and we will act promptly.